Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The company’s shares closed yesterday at p10,794. ...

Invest Ontario is partnering with AstraZeneca (AZN) to expand the company’s global R&D hub in Mississauga. This $820M investment underscores Ontario’s growing prominence in the life sciences ...

Thought LeaderMina MakarSenior Vice President, Global CVRMAstraZeneca NewsMedical spoke with Mina Makar, Senior Vice President of Global CVRM at AstraZeneca, about groundbreaking research in Heart ...

The positive recommendation from NICE for osimertinib was based on results from the ADAURA Phase III trial. In which, adjuvant treatment (after surgery) with osimertinib in patients with stage II ...

AstraZeneca (NASDAQ:AZN ... I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab precision drug to treat a type of ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...

Jan 17 (Reuters) - AstraZeneca (AZN.L), opens new tab has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times ...

FDA approves AstraZeneca's Datroway ... of Datroway was consistent with the known profile of this medicine, with no new safety concerns identified. In the Datroway arm, the interstitial lung ...

A targeted cancer therapy from AstraZeneca’s alliance with Daiichi Sankyo is now FDA approved to treat certain cases of advanced breast cancer, giving the British pharmaceutical giant another ...

AstraZeneca PLC AZN-Q is investing $820-million and creating more than 700 jobs in Ontario’s life sciences industry, stimulating growth within a national research and development sector that has ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...